Apr 5, 2011 by Brian Orelli, PhDSuit Settlement Sends Shares SkyrocketingCubist Pharmaceuticals gets concessions as it settles its patent suit with Teva.
Apr 5, 2011 by Brian Orelli, PhDObese Expectations Trump Great DataSorry VIVUS and Orexigen, you're still not going to get your drugs approved quickly.
Apr 4, 2011 by Brian Orelli, PhDPfizer Tests the Breakup WatersSale of Capsugel could be a good sign.
Apr 4, 2011 by Brian Orelli, PhDAnti-Infective, Very EffectiveThe FDA seems to like Optimer's new antibiotic.
Mar 31, 2011 by Brian Orelli, PhDGilead's Long-Term Cancer FightAn academic partnership is a good sign it's serious.
Mar 31, 2011 by Brian Orelli, PhDBetter Buy? Seattle Genetics or ImmunoGenBattle of the heat-seeking cellular missiles.
Mar 31, 2011 by Brian Orelli, PhDDrug Warning Labels: The Good, Bad, and UglyThey come in all shapes and sizes.
Mar 31, 2011 by Brian Orelli, PhDJohnson & Johnson Hires a BabysitterJ&J tries to turn the OTC business around.
Mar 30, 2011 by Brian Orelli, PhDThis Share Count Might Need Some Obesity Meds SoonArena gets some dilutive financing.
Mar 30, 2011 by Brian Orelli, PhDHow to Play the Pfizer Breakup (If It Happens)The sum of the parts could be worth more than the hole.
Mar 29, 2011 by Brian Orelli, PhDShould Big Biotech Pay Dividends?All grown up and no payouts to offer.
Mar 29, 2011 by Brian Orelli, PhDPartnership Now, Payoff LaterARIAD signs up a partner to develop a companion diagnostic.
Mar 29, 2011 by Brian Orelli, PhDMedtronic's Exciting New ToysThe device maker received multiple approvals in less than a week.
